BOLD
Boundless Bio, Inc.1.1400
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
25.52MP/E (TTM)
-Basic EPS (TTM)
-2.66Dividend Yield
0%Recent Filings
8-K
Q4 results, $108M cash runway
Boundless Bio reported Q4 and full-year 2025 results, with cash at $107.6 million funding operations into H2 2028 through KOMODO-1 proof-of-concept for BBI-940, now enrolling in breast cancer patients. R&D expenses dropped to $9.8 million in Q4 from $13.3 million, net loss narrowed to $12.9 million. Board member Christine Brennan resigned March 3 for a J&J role, no disagreements. POTENTIATE trial enrollment ceased to prioritize BBI-940.
10-K
FY2025 results
Boundless Bio posted FY2025 net loss of $58.2M, improved from $65.4M in FY2024, on $44.8M R&D spend down 19% y/y amid portfolio prioritization to BBI-940 kinesin degrader after halting POTENTIATE and STARMAP trials. Q4 R&D fell sharply as wind-downs advanced, with $117.6M cash extending runway into H2 2028 to fund KOMODO-1 Phase 1 initiation in Feb 2026 targeting ER+/HER2- breast and TNBC-LAR cancers. No revenue; $69.8M lease commitment through 2034 strains liquidity. Cash burn slowed. Clinical delays threaten runway.
8-K
Q3 loss narrows; trials advance
Boundless Bio reported Q3 2025 net loss of $13.9 million, down from $16.5 million year-over-year, with R&D expenses dropping to $10.7 million amid ongoing enrollment in the BBI-355/BBI-825 combination arm of the POTENTIATE trial. Cash reserves stood at $117.6 million, funding operations through first-half 2028 and proof-of-concept data for both programs. An IND submission for BBI-940 remains on track for a Phase 1 trial start in early 2026. Early-stage trials carry inherent uncertainties.
10-Q
Q3 FY2025 results
Boundless Bio narrowed its Q3 FY2025 net loss to $13.9 million from $16.5 million a year earlier, as operating expenses dropped 19% year-over-year to $15.1 million, driven by a 24% cut in research and development costs to $10.7 million following workforce reductions and the wind-down of underperforming trial arms. The company posted a $0.62 diluted EPS loss, improved from $0.74, with 22.4 million shares outstanding aligning neatly with the calculation. Cash burn eased, leaving $117.6 million in cash and short-term investments at quarter-end, bolstered by $4.2 million in year-to-date interest income yet tempered by no debt and a hefty $49.8 million non-current lease liability. Portfolio focus sharpened on the BBI-355/BBI-825 combo in the POTENTIATE trial and BBI-940's IND push, extending runway into early 2028. No non-GAAP metrics disclosed in the 10-Q. Clinical setbacks loom large, with early trial toxicities potentially derailing progress.
10-Q
Q2 FY2025 results
Boundless Bio trimmed operating expenses to $17.1M in Q2 FY2025 ended June 30, 2025, down 12.0% y/y from $19.4M, as R&D costs fell 17.1% y/y to $12.2M amid portfolio prioritization that cut BBI-825 monotherapy spending while ramping the BBI-355/BBI-825 combination arm in the POTENTIATE trial. Net loss narrowed to $15.7M or $0.70 per diluted share, from $17.0M or $0.77, buoyed by $1.4M in interest income; YTD, losses eased 3.0% y/y to $31.4M on $34.4M expenses. Cash burn slowed, with operating cash use at $26.4M YTD versus $32.0M y/y, leaving $127.1M in cash and equivalents to fund into H1 2028. No debt burdens the balance sheet. Yet clinical timelines remain unpredictable.
BBOT
BridgeBio Oncology Therapeutics
11.85-0.15
BCAB
BioAtla, Inc.
0.76-0.01
BDTX
Black Diamond Therapeutics, Inc
2.62-0.03
BNTX
BioNTech SE
92.23-1.52
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
BPTH
Bio-Path Holdings, Inc.
0.08+0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
XBIO
Xenetic Biosciences, Inc.
2.07-0.27